Internship

Immunology Co-op

Posted on 9/16/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Cambridge, MA, USA

Winter/Spring internship opportunity in Cambridge, MA from 1/21/25- 6/20/25. Applicants must be available for the entire duration of the internship.

Category
Lab & Research
Life Sciences
Medical Research
Required Skills
Data Analysis
Requirements
  • Currently enrolled in a Master’s or PhD program in Immunology, Cell Biology, Molecular Biology, or a related field.
  • Hands-on experience with Flow Cytometry, ELISA, Luminex, and cell-based assays is required.
  • Strong analytical and problem-solving skills with the ability to interpret complex data.
  • Excellent organizational skills and attention to detail.
  • Ability to work independently and collaboratively within a team.
  • Proficient in data analysis software (e.g., FlowJo, GraphPad Prism) and Microsoft Office Suite.
  • Strong verbal and written communication skills.
Responsibilities
  • Design, execute, and analyze Flow Cytometry experiments to characterize immune cell populations and assess functional markers.
  • Perform ELISA and Luminex assays to quantify cytokines, chemokines, and other soluble factors in biological samples.
  • Conduct cell-based assays to evaluate immune cell function, including proliferation, cytotoxicity, and cytokine production.
  • Maintain accurate and detailed records of experiments, including data analysis and interpretation.
  • Assist in the development and optimization of new protocols for immunological assays.
  • Collaborate with cross-functional teams to support ongoing research projects.
  • Present experimental findings in lab meetings and contribute to the preparation of scientific manuscripts.
  • Ensure compliance with all safety and regulatory requirements within the laboratory.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional pharmaceuticals, which often rely on small molecules or proteins, Moderna's mRNA-based therapies aim to enhance the speed and efficiency of drug discovery and manufacturing. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create effective treatments for a range of health conditions.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

15%

2 year growth

48%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's AI-driven drug discovery accelerates novel mRNA-based therapeutics identification.
  • Expansion in Asia enhances global supply chain and reduces production costs.
  • mRNA technology is gaining traction for non-infectious disease vaccines, like cancer.

What critics are saying

  • Potential Nasdaq 100 removal could impact stock visibility and investor interest.
  • Bypassing safety steps in Australia may raise regulatory and public scrutiny concerns.
  • Hong Kong's reluctance to receive Covid-19 jab affects market penetration and sales.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company focuses on mRNA's potential to transform drug discovery and manufacturing.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE